20 强制药公司获得 FDA 批准情况的比较分析（2014-2023 年）。

IF 6.5 2区医学 Q1 PHARMACOLOGY & PHARMACY

Drug Discovery Today Pub Date : 2024-08-05 DOI:10.1016/j.drudis.2024.104128

Alexander Schuhmacher , Oliver Gassmann , Markus Hinder , Dominik Hartl

{"title":"20 强制药公司获得 FDA 批准情况的比较分析（2014-2023 年）。","authors":"Alexander Schuhmacher , Oliver Gassmann , Markus Hinder , Dominik Hartl","doi":"10.1016/j.drudis.2024.104128","DOIUrl":null,"url":null,"abstract":"<div><p>This article addresses the research and development (R&D) productivity challenge of the pharmaceutical industry, focusing on United States Food and Drug Administration (FDA)-related new drug approvals of the top 20 pharmaceutical companies (2014–2023). We evaluated the degree of innovation in new drugs to determine the innovativeness of these leading companies. A key finding of our analysis is the decline in the number of new drugs approved by the FDA for these leading companies over the investigated time period. This trend suggests that some of the leading companies are losing ground in R&D innovation, raising concerns about their ability to sustain competitive advantage, ensure long-term market success, and maintain viable business models.</p></div>","PeriodicalId":301,"journal":{"name":"Drug Discovery Today","volume":"29 9","pages":"Article 104128"},"PeriodicalIF":6.5000,"publicationDate":"2024-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1359644624002538/pdfft?md5=41432e6fdcef9771d76b188b79fa8261&pid=1-s2.0-S1359644624002538-main.pdf","citationCount":"0","resultStr":"{\"title\":\"Comparative analysis of FDA approvals by top 20 pharma companies (2014–2023)\",\"authors\":\"Alexander Schuhmacher , Oliver Gassmann , Markus Hinder , Dominik Hartl\",\"doi\":\"10.1016/j.drudis.2024.104128\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>This article addresses the research and development (R&D) productivity challenge of the pharmaceutical industry, focusing on United States Food and Drug Administration (FDA)-related new drug approvals of the top 20 pharmaceutical companies (2014–2023). We evaluated the degree of innovation in new drugs to determine the innovativeness of these leading companies. A key finding of our analysis is the decline in the number of new drugs approved by the FDA for these leading companies over the investigated time period. This trend suggests that some of the leading companies are losing ground in R&D innovation, raising concerns about their ability to sustain competitive advantage, ensure long-term market success, and maintain viable business models.</p></div>\",\"PeriodicalId\":301,\"journal\":{\"name\":\"Drug Discovery Today\",\"volume\":\"29 9\",\"pages\":\"Article 104128\"},\"PeriodicalIF\":6.5000,\"publicationDate\":\"2024-08-05\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S1359644624002538/pdfft?md5=41432e6fdcef9771d76b188b79fa8261&pid=1-s2.0-S1359644624002538-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Drug Discovery Today\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1359644624002538\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug Discovery Today","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1359644624002538","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

摘要

本文探讨了制药行业的研发（R&D）生产力挑战，重点关注美国食品和药物管理局（FDA）与排名前 20 的制药公司的新药批准情况（2014-2023 年）。我们评估了新药的创新程度，以确定这些领先公司的创新能力。我们分析的一个重要发现是，在调查期内，这些领先公司获得美国食品及药物管理局批准的新药数量有所下降。这一趋势表明，一些领先公司在研发创新方面正在失去优势，从而引发了人们对其能否保持竞争优势、确保长期市场成功以及维持可行商业模式的担忧。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Comparative analysis of FDA approvals by top 20 pharma companies (2014–2023)

This article addresses the research and development (R&D) productivity challenge of the pharmaceutical industry, focusing on United States Food and Drug Administration (FDA)-related new drug approvals of the top 20 pharmaceutical companies (2014–2023). We evaluated the degree of innovation in new drugs to determine the innovativeness of these leading companies. A key finding of our analysis is the decline in the number of new drugs approved by the FDA for these leading companies over the investigated time period. This trend suggests that some of the leading companies are losing ground in R&D innovation, raising concerns about their ability to sustain competitive advantage, ensure long-term market success, and maintain viable business models.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Drug Discovery Today 医学-药学

CiteScore

14.80

自引率

2.70%

发文量

293

审稿时长

6 months

期刊介绍： Drug Discovery Today delivers informed and highly current reviews for the discovery community. The magazine addresses not only the rapid scientific developments in drug discovery associated technologies but also the management, commercial and regulatory issues that increasingly play a part in how R&D is planned, structured and executed. Features include comment by international experts, news and analysis of important developments, reviews of key scientific and strategic issues, overviews of recent progress in specific therapeutic areas and conference reports.